What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
Number of studies
3
Safety
Requires caution
Time to effects
Not applicable — a diagnostic pathway preceding any possible start of therapy, usually taking several weeks.
Who it's for
Table of contents
TL;DR
Before a physician can qualify a patient for testosterone therapy, a far broader panel of tests is needed than testosterone level alone. The full list of blood tests, symptom questionnaires, and criteria that determine whether TRT is safe and appropriate.
- →Distinguishes genuine hypogonadism from a transiently low or borderline result
- →Identifies whether the cause lies in the testes, the pituitary, or SHBG — which changes subsequent management
- →Catches contraindications (elevated PSA, untreated erythrocytosis) before therapy is started
| Total testosterone (2x morning, 7:00–10:00) | The basis of diagnosis; threshold <300 ng/dL per AUA, confirmed by 2 separate measurements |
|---|---|
| Free testosterone + SHBG | For borderline results or factors that alter SHBG (obesity, diabetes, hypothyroidism) |
| LH, FSH | Differentiates primary hypogonadism (testes) from secondary (pituitary/hypothalamus) |
| Prolactin | Rules out hyperprolactinemia and a pituitary adenoma as a secondary cause |
| Estradiol (E2) | Baseline value before TRT — a reference point for monitoring and assessing gynecomastia |
| Complete blood count (hemoglobin, hematocrit) | TRT must be deferred if there's untreated erythrocytosis / hematocrit above the upper reference limit |
| PSA | For men ≥40; PSA ≥4 ng/mL (or ≥3 ng/mL with elevated risk) requires a urology consultation before TRT |
| Digital rectal exam (DRE) | Prostate assessment alongside PSA, before qualification |
| Lipid panel | Baseline cardiovascular risk assessment |
| Fasting glucose / HbA1c | Assesses carbohydrate metabolism — insulin resistance is a common cause of secondarily low testosterone |
| Liver function tests (ALT, AST) | Metabolic safety, particularly relevant when considering oral forms |
| TSH | Rules out hypothyroidism as a reversible cause of symptoms |
| Symptom questionnaire (ADAM / AMS) | A structured assessment of clinical symptoms alongside the lab results |
| Sleep apnea screening (e.g., STOP-BANG) | For suspected OSA — referral for polysomnography before qualifying for TRT |
Understand
Overview
The decision to start testosterone replacement therapy should never rest on a single blood test result, or on a patient's own sense that they're "lacking energy." Endocrine Society, American Urological Association (AUA), and European Association of Urology (EAU) guidelines all describe TRT as a clinical decision requiring a full diagnostic panel — one that confirms hormonal deficiency, differentiates its cause, rules out reversible conditions, and assesses safety before any therapy is started. This piece is a practical, complete checklist of the tests actually run before TRT — explaining what each one is for and in what order they're typically ordered.
The diagnostic process has a funnel structure. At the very entry point is symptom assessment — a structured interview or questionnaire (most often ADAM, Androgen Deficiency in Aging Males, less often AMS), which helps separate patients with a real likelihood of testosterone deficiency from those whose fatigue or low libido stems from something else entirely — depression, sleep deprivation, chronic stress, or medication side effects. The questionnaire alone doesn't establish a diagnosis, but it qualifies a patient for further, more expensive laboratory work-up.
The second stage is hormonal confirmation — total testosterone measured in the morning, twice, on separate days. Only after confirming a low result does the physician move to the differentiating panel, which answers the question "why is testosterone low" — LH, FSH, prolactin, SHBG, free testosterone, and estradiol. This stage determines whether the problem lies in the testes (primary hypogonadism), in the hypothalamic-pituitary axis (secondary), or whether total testosterone is artificially lowered by abnormal SHBG while the actual pool of biologically active hormone is normal.
The third, equally important stage is the safety panel — tests that don't confirm hypogonadism, but answer the question of whether the patient can safely start testosterone therapy at all. Complete blood count with hematocrit, PSA and a digital rectal exam, a lipid panel, fasting glucose or HbA1c, and liver function tests — each of these results can, on its own, disqualify a patient from immediately starting TRT or route them first to another specialist (urologist, hematologist, cardiologist).
The final, often-skipped element is actively looking for reversible causes of low testosterone — obesity, untreated sleep apnea, hypothyroidism, hyperprolactinemia, or chronic opioid or glucocorticoid use. In a significant share of men, correcting these factors raises testosterone to normal values without needing lifelong hormone therapy — which is why solid diagnostic work-up before TRT isn't a formality, but a genuine opportunity to avoid unnecessary treatment.
Mechanism of action
The rationale behind every element of the pre-treatment panel follows directly from the physiology of the hypothalamic-pituitary-gonadal axis and from the documented effects of testosterone beyond the reproductive system. LH and FSH aren't an add-on to testosterone — they're the key to locating the problem. Elevated LH/FSH with low testosterone points to damage in the testes themselves (the pituitary is "shouting," but the testes aren't responding), while low or inappropriately normal LH/FSH suggests a disorder higher up — at the pituitary or hypothalamus level, which often requires additional imaging (e.g., pituitary MRI) before deciding on TRT. This distinction also matters for fertility: TRT further suppresses the body's own hormonal axis and spermatogenesis, so in men planning children, baseline LH/FSH is a reference point when considering alternatives (e.g., hCG) instead of classic testosterone therapy.
The second pillar of the rationale is hematology. Testosterone stimulates erythropoiesis through two pathways — it raises erythropoietin concentration and simultaneously suppresses hepatic hepcidin production, which makes iron absorption easier and boosts red blood cell production. In some men this effect is strong enough to cause erythrocytosis — a thickening of the blood that raises the risk of venous thrombosis and cardiovascular events, particularly in the first year of therapy. That's why hematocrit and a complete blood count must be measured before the first dose of testosterone — without a baseline, safe monitoring simply isn't possible, and an already elevated baseline hematocrit is on its own a reason to defer TRT until its cause is investigated.
The third pillar is the prostate gland. Testosterone doesn't initiate prostate cancer, but prostate tissue — including a potentially present, subclinical cancerous focus — is androgen-sensitive, especially during the transition from very low to physiological concentrations (the so-called saturation model). PSA and a digital rectal exam before TRT aren't meant to diagnose prostate cancer — they're meant to catch patients whose elevated risk requires a urology consultation first; therapy is only safe to start once that's been ruled out.
The fourth pillar is metabolism and the cardiovascular system. Low testosterone correlates with metabolic syndrome, insulin resistance, and an unfavorable lipid profile, but the relationship also runs the other way — visceral obesity increases peripheral aromatization of testosterone to estradiol and deepens suppression of the hypothalamic-pituitary axis through leptin resistance. A lipid panel, fasting glucose or HbA1c, and liver function tests don't just give a baseline picture of cardiovascular risk before any TRT effect — they also help assess whether the observed testosterone deficiency is a secondary consequence of untreated obesity or diabetes, conditions whose treatment can itself raise testosterone.
The fifth pillar concerns sleep and the thyroid. Untreated obstructive sleep apnea causes nocturnal hypoxia and fragmented sleep, which disrupt pulsatile LH secretion and lower testosterone independent of any testicular or pituitary pathology — and at the same time, testosterone therapy itself can worsen sleep apnea, so ruling it out or treating it before TRT matters on both sides of that equation. Similarly, hypothyroidism and hyperprolactinemia are common, fully reversible causes of secondarily low testosterone that need to be ruled out before deciding on lifelong hormone therapy.
Step 1: Symptom assessment
A clinical interview or the ADAM/AMS questionnaire qualifies the patient for further, more expensive laboratory work-up.
Step 2: First morning total testosterone measurement
Blood drawn between 7:00 and 10:00, due to the hormone's circadian secretion rhythm.
Step 3: Confirmation with a second morning measurement
The result must be repeated on a separate day — a single abnormal result is never grounds for a diagnosis.
Step 4: Differentiating the cause
LH, FSH, prolactin, SHBG, and free testosterone show whether the problem lies in the testes, the pituitary, or the binding protein.
Step 5: Safety panel before qualification
Hematocrit, PSA with DRE, lipid panel, HbA1c, and liver function tests determine whether TRT can be started safely right away.
Step 6: Ruling out reversible causes
TSH, body weight assessment, and sleep apnea screening identify conditions whose treatment might raise testosterone without TRT.
Evidence: strong — based on 3 studies in this database.
Benefits
Common myths
MythA single testosterone result below the reference range is enough to start TRT.
FactGuidelines require confirmation with at least two separate, morning measurements plus the presence of specific clinical symptoms — a result on its own, without that context, isn't sufficient.
MythA complete blood count and PSA are "just in case" tests that can be skipped if the patient feels fine.
FactThese are safety tests, not comfort tests — elevated hematocrit or PSA can, on their own, disqualify a patient from immediately starting TRT regardless of how they feel.
MythLow testosterone always means the testes have stopped working.
FactIn many men the cause is a reversible factor — obesity, untreated sleep apnea, hypothyroidism, or chronic stress — which, once treated, can raise testosterone without needing TRT.
MythFree testosterone is more important than total and should be measured first.
FactTotal testosterone remains the first-line test; free testosterone and SHBG are only measured for borderline results or factors that alter the binding protein's level.
Forms & variants
What Tests Are Needed Before TRT? The Complete Pre-Treatment Testing List comes in several forms that differ in bioavailability and use case — the form you pick genuinely matters for how effective the supplementation is.
Basic (screening) panel
Total testosterone (2x morning), LH, FSH, prolactin, complete blood count with hematocrit, PSA with DRE.
Best for: Most men reporting typical symptoms of testosterone deficiency without additional risk factors
Extended panel
The basic panel plus free testosterone, SHBG, estradiol, lipid panel, HbA1c, liver function tests, and TSH.
Best for: Patients with obesity, metabolic syndrome, borderline results, or those planning long-term therapy
Elevated-risk panel
The extended panel plus a urology consultation, sleep apnea screening (STOP-BANG/polysomnography), and hematologic evaluation for an already elevated baseline hematocrit.
Best for: Men over 50, with a family history of prostate cancer, severe obesity, or abnormal blood counts
Practice
Frequently asked questions
The basic panel (testosterone 2x, LH, FSH, prolactin, complete blood count, PSA) is essentially mandatory. The extended panel and additional tests (SHBG, lipid panel, HbA1c, sleep apnea screening) are chosen individually by the physician, depending on initial results and the patient's risk factors.
Testosterone concentration fluctuates day to day and follows a circadian rhythm, so a single abnormal result isn't a reliable basis for diagnosis. Guidelines require confirming a low result with a second, separate morning measurement.
PSA ≥4 ng/mL (or ≥3 ng/mL with elevated prostate cancer risk, e.g., in men with a family history) requires a urology consultation before considering TRT — therapy isn't started until the cause of the elevated result has been investigated.
Not always — sometimes it's enough to identify and correct the cause (e.g., dehydration, smoking, untreated sleep apnea) for hematocrit to return to normal and therapy to become possible. During TRT itself, hematocrit above roughly 54% is grounds for reducing the dose, changing the delivery form, or temporarily pausing treatment.
Testosterone and hypothalamic-pituitary axis hormones don't require strict fasting, but glucose and the lipid panel do — usually 8–12 hours without food. The simplest approach is to schedule one morning fasting blood draw covering the whole panel.
Usually several weeks — the process itself involves two separate morning testosterone measurements, the differentiating and safety panels, and sometimes additional specialist consultations (urologist, hematologist) if the results call for them.
Dosage & timing
Typical dose
Not applicable — this piece describes the full diagnostic pathway preceding TRT, not a drug dosing schedule
Form
Blood tests: total testosterone (2x morning), free testosterone, SHBG, LH, FSH, prolactin, estradiol, complete blood count with hematocrit, PSA, lipid panel, fasting glucose or HbA1c, liver function tests, TSH; plus a digital rectal exam and an ADAM/AMS symptom questionnaire
Blood for testosterone is drawn fasting or after a light meal, always in the morning; before PSA it's best to have 48 hours without ejaculation or intense physical exertion; a single abnormal result is never sufficient on its own for a diagnosis or a treatment decision.
Best times to take it
- Total testosterone measured only in the morning, between 7:00 and 10:00, due to the hormone's circadian secretion rhythm
- A second testosterone measurement on a separate day to confirm the result — never on the same day as the first
- PSA and a DRE are best ordered at least 48 hours after the last ejaculation and without prior intense exertion (e.g., cycling)
- The metabolic panel (glucose, lipids) usually requires 8–12 hours of fasting
- The entire process — from the first visit to qualification — usually takes several weeks, given the need to repeat measurements and potentially arrange specialist consultations
Safety
Side effects & contraindications
Possible side effects
Not applicable — this is a diagnostic process, not a pharmacological intervention
Possible minor discomfort from the blood draw itself (bruising at the puncture site, rarely a vasovagal reaction)
Contraindications
Untreated erythrocytosis / hematocrit above the upper limit of the laboratory reference range — requires investigating the cause before TRT
PSA ≥4 ng/mL (or ≥3 ng/mL with elevated prostate cancer risk) without a prior urology consultation
An abnormal digital rectal exam suggesting prostate pathology
Active or suspected breast cancer in a man, or prostate cancer
Severe, untreated obstructive sleep apnea
Uncompensated, advanced heart failure (NYHA class III/IV)
Near-term plans to have children without a prior fertility consultation — TRT suppresses endogenous spermatogenesis
Interactions
High-dose biotin (vitamin B7) can distort immunoassay hormone results, including testosterone, TSH, and PSA — it's recommended to stop the supplement 2–3 days before the blood draw
Opioids and chronic glucocorticoid use lower testosterone independent of true hypogonadism and are worth noting in the patient's history
5-alpha-reductase inhibitors (finasteride, dutasteride) can lower PSA by as much as half, potentially masking real risk and requiring an adjusted interpretation of the result
Recent ejaculation, cycling, or a digital rectal exam shortly before the blood draw can temporarily raise PSA and skew the result
Is it worth taking?
Who it's for
- Men with symptoms suggesting testosterone deficiency (reduced libido, erectile dysfunction, chronic fatigue, loss of muscle mass) considering TRT
- Patients who already have one low testosterone result and need a full work-up before qualifying for treatment
- Physicians preparing a patient to safely start testosterone therapy
Not for
- Untreated erythrocytosis / hematocrit above the upper limit of the laboratory reference range — requires investigating the cause before TRT
- PSA ≥4 ng/mL (or ≥3 ng/mL with elevated prostate cancer risk) without a prior urology consultation
- An abnormal digital rectal exam suggesting prostate pathology
- Active or suspected breast cancer in a man, or prostate cancer
- Severe, untreated obstructive sleep apnea
- Uncompensated, advanced heart failure (NYHA class III/IV)
- Near-term plans to have children without a prior fertility consultation — TRT suppresses endogenous spermatogenesis
Evidence
Worth knowing
Testosterone follows a circadian rhythm — concentrations are highest in the morning, so a reliable measurement must be taken between 7:00 and 10:00.
PSA ≥4 ng/mL (or ≥3 ng/mL with elevated risk) requires a urology consultation before any decision about TRT.
Hematocrit above the upper limit of the laboratory reference range is one of the few results that on its own defers the start of testosterone therapy.
Testosterone boosts erythropoiesis by raising erythropoietin and suppressing hepcidin — which is why a complete blood count is a mandatory test, not an optional one.
Obesity, sleep apnea, and hypothyroidism are among the most common reversible causes of secondarily low testosterone.
High-dose biotin can distort testosterone, TSH, and PSA results — it's worth stopping the supplement a few days before the blood draw.
Studies
Clinicians should not start testosterone therapy in men with a baseline hematocrit above the upper limit of the laboratory reference range without discussing the increased risk of erythrocytosis and the need for close monitoring.
Bhasin S et al. (Endocrine Society guideline), Journal of Clinical Endocrinology & Metabolism, 2018
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
Strong evidenceBhasin S, Brito JP, Cunningham GR i wsp. · Journal of Clinical Endocrinology & Metabolism · 2018
Clinical guidelines describing the full diagnostic panel before TRT, including hematocrit and PSA criteria as contraindications to immediately starting therapy.
View studyEvaluation and Management of Testosterone Deficiency: AUA Guideline
Strong evidenceMulhall JP, Trost LW, Brannigan RE i wsp. · The Journal of Urology · 2018
American Urological Association guidelines defining the <300 ng/dL threshold that supports a diagnosis of testosterone deficiency and the scope of testing preceding qualification for treatment.
View studyManagement of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide
Moderate evidenceAgrawal P, Singh SM, Kohn T · European Urology Focus · 2023
A practical guide to assessing and monitoring hematocrit before and during testosterone therapy, with decision thresholds for dose reduction or discontinuation.
View studySources & bibliography
- Bhasin et al. 2018 — Endocrine Society Guideline
- Mulhall et al. 2018 — AUA Guideline
- Agrawal et al. 2023 — Management of Erythrocytosis
Citations are illustrative for this demo version and require full bibliographic verification by the editorial team before production publication.
Compare with similar entries
About the authors of this entry
Author
dr Piotr ZielińskiEndocrinologist
Piotr reviews content on hormones, metabolic health and supplement pharmacology.
131 publications on this site
Medical review
dr Anna KowalczykEditor-in-Chief, Molecular Biology
Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.
50 publications on this site
Related entries
4.6Hypogonadism — Diagnosis and Criteria for TRT Eligibility
Not every low testosterone result means hypogonadism requiring treatment. We explain which laboratory and symptomatic criteria must be met before TRT becomes a justified option.
4.4TRT — Administration Forms: Injections, Gels, and Patches
Injections, transdermal gels, and patches — the three main forms of testosterone replacement therapy differ in blood-concentration profile, ease of use, and the risk of transferring the hormone to other people.
4.5SHBG (Sex Hormone-Binding Globulin)
A transport protein whose level determines how much testosterone is actually 'available' to tissues — without knowing SHBG, a total testosterone result alone can be misleading.
4.3PSA and Prostate Health
Prostate-specific antigen is one of the most commonly ordered tests in men over 50 — but also one of the most controversial, due to a high false-positive rate.
4.6Complete Blood Count (CBC)
The most commonly ordered laboratory test in the world — a seemingly simple printout hides information about immunity, oxygen transport, and blood clotting, if you know what to look for.
4.5How to Read a Basic Blood Test Panel
CBC, lipid panel, glucose, TSH — how to read the results of a basic blood panel so you catch early signals of a problem before it becomes a disease.
4.7How Often to Test Testosterone on TRT? Monitoring Schedule and Checkups
Starting testosterone therapy isn't the end of diagnostics — it's the start of a new, recurring rhythm of checkups. We explain which tests happen at month 3, which at year one, and which need repeating for as long as therapy continues — and how the schedule differs between injectable and gel forms.
4.6Testosterone — What's Normal for a Man? Results, Age, and When It Becomes a Problem
The 'normal' range printed on your lab report doesn't mean quite what it seems — reference ranges vary between labs, assay methods, and the population they were derived from. We explain how to actually read a testosterone result, how it changes with age, and when a 'low-normal' result is already a clinical problem.
Related articles
PoradnikiTRT or Lifestyle Change? What Actually Raises Testosterone Before You Consider Therapy
Before considering testosterone replacement therapy, it's worth checking how much sleep, training, and fat loss can realistically achieve — and when these interventions genuinely aren't enough.
July 29, 2026
PoradnikiTRT Step by Step — What Does Starting Testosterone Therapy Actually Look Like?
From the first suspicion that "something's off" to a stable maintenance dose usually takes several months, not a few days — we walk through the entire, real process step by step, including the stages that most often disappoint at the start.
August 15, 2026
PoradnikiThe Most Common TRT Mistakes — 15 Things That Can Undermine Your Therapy's Results
A wrap-up of our entire testosterone therapy series: fifteen common, real mistakes — from diagnostics to discontinuation — that can turn a well-designed TRT protocol into a source of disappointment or genuine health risk.
August 15, 2026
PoradnikiNormal Testosterone, But You Feel Awful — Could You Still Have Hypogonadism?
A testosterone result that comes back "in range" on a lab printout doesn't always mean everything is hormonally fine — but it doesn't automatically mean you have hypogonadism either. We explain four real explanations for this mismatch, ranked by strength of evidence.
August 15, 2026
Comments (2)
- KW
Kasia W. 2 weeks ago
Very clearly explained, especially the interactions section — I hadn't seen it laid out this well anywhere else.
- MT
Marek T. a month ago
Are you planning to update this with the newest study from this year? I saw an interesting meta-analysis.